Cancer Center Support Grant

Rutgers Biomedical And Health Sciences, Newark NJ

Investigators

Linked publications, trials & patents

Abstract

Rutgers Cancer Institute is a matrix/consortium with Princeton University (PU) and is New Jersey’s only NCI-designated Comprehensive Cancer Center, serving a population of 9.2 million. The cancer institute focused the strengths and resources of the major research institutions in NJ on addressing the cancer burden in its catchment area (NJ). Rutgers Cancer Institute is an independent institute of Rutgers University (RU), optimizing its potential for growth and transdisciplinary collaboration. In FY2023, the cancer institute received over $140 million of institutional support (RU and PU, the State of NJ, the RWJBarnabas Health System [RWJBH], philanthropy). Metrics of success in this grant period include increases in: Center Members, PU Members, cancer focused peer reviewed support, NCI Institutional Training Grants, space, patient visits, interventional therapeutic trial accrual, State Support, and counties covered by ScreenNJ. Steven K. Libutti remains Cancer Center Director, Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences, and RWJBH Senior Vice President for Oncology Services since 2017. Rutgers Cancer Institute entered into an innovative Integrated Practice Agreement with RWJBH that provides a financially sustainable model for provision of high-quality, cutting-edge, academic oncology services, and enabled system-wide restructuring of the clinical trial enterprise and a significant increase in accruals. Driven by its Strategic Plan, Rutgers Cancer Institute increased high impact center science; supported efforts to train the next generation of cancer researchers and leaders; and increased the impact of the Community Outreach and Engagement Office on its catchment area. The CCSG Research Programs all demonstrated enhanced collaborations and scientific impact: 1) Cancer Metabolism and Immunology, 2) Genomic Instability and Cancer Genetics, 3) Cancer Pharmacology, 4) Clinical Investigations and Precision Therapeutics, and 5) Cancer Prevention and Control. The Research Programs are supported by shared resources (Biomedical Informatics, Biostatistics, Biorepository and Histopathology, Genome Editing, Comprehensive Genomics, Immune Monitoring/Flow Cytometry, Metabolomics and Cancer Prevention/ Outcomes Data Support) and other services. Rutgers Cancer Institute’s future is guided by a Strategic Plan that includes increasing access for NJ residents to screening (new ScreenNJ mobile unit); increasing trial accruals through an expanded clinical research infrastructure; improving faculty and trainee mentorship and leadership; increasing multi- project grants through strategic investment; and operationalizing the Jack and Sheryl Morris Cancer Center, NJ’s only free-standing cancer hospital.